Selection criteria for RCTs |
a. Recruiting patients with COPD |
b. Phase III or Phase IV randomised, double-blind, placebo-controlled trial, testing      i. Long-acting muscarinic antagonist (LAMA) OR      ii. Long-acting β-agonist (LABA) OR      iii. LAMA/LABA combination |
c. Primary outcomes were      i. spirometry parameter(s) OR      ii. COPD exacerbations OR      iii. mortality |
d. Duration of treatment was ≥24 weeks post-randomisation |
e. Enrolled ≥100 patients with COPD |
f. Medicine was tested at licensed dose |
Selection of patients with COPD from the OPCRD database |
a. Quality and Outcomes Framework (QOF) approved diagnostic code of COPD, which includes the requirement for a post-bronchodilator FEV1/FVC <0.70 [31] |
b. Registered in OPCRD with data extracted from general practice at least once after 1 January 2011. The index date was defined as the date of the last data extraction |
c. ≥1 year of data available prior to the index date to define RCT inclusion/exclusion criteria |
d. FEV1 and FVC recorded within 5Â years of the index date |
e. mMRC score recorded within 5Â years of index date |
f. Recorded valid blood eosinophil count ever |
g. Age ≥40 years |